Skip to main content
SpringerLink
Log in

SREBP-1 und Fettleber

Klinische Bedeutung für Diabetes, Adipositas, Dyslipidämie und Atherosklerose

SREBP-1 and fatty liver

Clinical relevance for diabetes, obesity, dyslipidemia and atherosclerosis

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Insulinresistenz und viszerale Fettverteilung spielen in aller Regel bei der Entstehung klinischer Facetten des metabolischen Syndroms (z. B. Dyslipidämie, Diabetes und Atherosklerose) eine entscheidende Rolle. In dieser Übersicht werden einige neuere Zusammenhänge mit der Fettleber skizziert, für deren Suszeptibilität zumindest im Tiermodell die Aktivität von Transkriptionsfaktoren in der Leber, wie z. B. von „sterol regulatory element-binding protein 1“ (SREBP-1), eine entscheidende Rolle spielt. Neben dieser molekularen Betrachtung wird auf therapeutische Lebensstilmaßnahmen wie z. B. Gewichtsreduktion eingegangen, die nicht nur mit einer Verbesserung der Insulinsensitivität, sondern auch mit Reduktion einer Fettleber assoziiert sind.

Abstract

Insulin resistance and visceral fat distribution usually play a major role in the development of clinical aspects of the metabolic syndrome, such as dyslipidemia, diabetes and atherosclerosis. In this review, the focus will be on some novel relationships with a fatty liver, for which susceptibility appears to be mediated by the activity of transcription factors, such as sterol regulatory element-binding protein 1 (SREBP-1). In addition to this molecular aspect therapeutic life-style modifications, such as weight reduction which are associated with increased insulin sensitivity and a decrease of fat in the liver will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112:2735–2752

    Article  PubMed  Google Scholar 

  2. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  PubMed  CAS  Google Scholar 

  3. Ludwig J, Viggiano TR, McGill DB et al (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438

    PubMed  CAS  Google Scholar 

  4. Donnelly KL, Smith CI, Schwarzenberg SJ et al (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351

    PubMed  CAS  Google Scholar 

  5. Day CP, James OF (1998) Steatohepatitis: a tale of two „hits“? Gastroenterology 114:842–845

    Article  PubMed  CAS  Google Scholar 

  6. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923

    Article  PubMed  Google Scholar 

  7. Pagano G, Pacini G, Musso G et al (2002) Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35:367–372

    Article  PubMed  CAS  Google Scholar 

  8. Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132:2191–207

    Article  PubMed  CAS  Google Scholar 

  9. Charlton M, Sreekumar R, Rasmussen D et al (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35:898–904

    Article  PubMed  CAS  Google Scholar 

  10. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481

    Article  PubMed  CAS  Google Scholar 

  11. Rabøl R, Petersen KF, Dufour S et al (2011) Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A 108:13705–13709

    Article  PubMed  Google Scholar 

  12. Petersen KF, Dufour S, Savage DB et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104:12587–12594

    Article  PubMed  CAS  Google Scholar 

  13. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131

    PubMed  CAS  Google Scholar 

  14. Matsumoto M, Han S, Kitamura T et al (2006) Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 116:2464–2472

    PubMed  CAS  Google Scholar 

  15. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95–96

    Article  PubMed  CAS  Google Scholar 

  16. Cheng Z, White MF (2011) Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 14:649–661

    Article  PubMed  CAS  Google Scholar 

  17. Knebel B, Haas J, Hartwig S et al (2012) Liver specific expression of transcriptional active SREBP-1c is associated with fatty liver and increase fat mass. PLoS One 7(2):e31812

    Article  PubMed  CAS  Google Scholar 

  18. Kotzka J, Knebel B, Haas J et al (2012) Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity. PLoS One, 7(2):e32609

    Google Scholar 

  19. Kotzka J, Knebel B, Janssen OE et al (2011) Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolidaemia. Atherosclerosis 218:134–143

    Article  PubMed  CAS  Google Scholar 

  20. McGarry JD (1992) What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258:766–770

    Article  PubMed  CAS  Google Scholar 

  21. Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al (2008) Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7:125–134

    Article  PubMed  CAS  Google Scholar 

  22. Unger RH (2002) Lipotoxic diseases. Annu Rev Med 53:19–36

    Article  Google Scholar 

  23. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340

    Article  PubMed  CAS  Google Scholar 

  24. Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 96:11041–11048

    Article  PubMed  CAS  Google Scholar 

  25. Kotzka J, Müller-Wieland D (2004) Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets 8:141–149

    Article  PubMed  CAS  Google Scholar 

  26. Tang JJ, Li JG, Qi W et al (2011) Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab 13:44–56

    Article  PubMed  CAS  Google Scholar 

  27. Li Y, Xu S, Mihaylova MM et al (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376–388

    Article  PubMed  CAS  Google Scholar 

  28. Look AHEAD Research Group (2010) Long-term effects of a lifestyle intervention on weight in cardiovascular risk factors in individuals with type-2-diabetes mellitus. 4-Year results of the Look AHEAD trial. Arch intern Med 170:1566–1575

    Article  Google Scholar 

  29. Lazo M, Solga SF, Horska A et al (2010) Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type-2-diabetes. Diabetes Care 33:2156–2163

    Article  PubMed  Google Scholar 

  30. Petersen KF, Dufour S, Befroy D et al (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608

    Article  PubMed  CAS  Google Scholar 

  31. Stefan N, Kantarzis K, Häring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29:939–960

    Article  PubMed  CAS  Google Scholar 

  32. Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38

    Article  PubMed  CAS  Google Scholar 

  33. World Health Organisation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of WHO consultation. WHO/NCO/NCS/99.2

  34. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16(5):442–443

    Article  PubMed  CAS  Google Scholar 

  35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  36. Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252

    PubMed  Google Scholar 

  37. International Diabetes Federation. Worldwide definition of the metabolic syndrome.available http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf (accessed 2005 Aug 24)

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Herz-, Gefäß- und Diabeteszentrum u. Abteilung für Allgemeine Innere Medizin, Asklepios Klinik St. Georg, Asklepios Campus Hamburg, Medizinische Fakultät der Semmelweis-Universität, Lohmühlenstr. 5, 20099, Hamburg, Deutschland

    D. Müller-Wieland & J. Haas

  2. Institut für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes-Zentrum, Leibniz-Institut für Diabetesforschung, Heinrich-Heine-Universität, Düsseldorf, Deutschland

    B. Knebel & J. Kotzka

Authors
  1. D. Müller-Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Knebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Kotzka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Müller-Wieland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller-Wieland, D., Knebel, B., Haas, J. et al. SREBP-1 und Fettleber. Herz 37, 273–280 (2012). https://doi.org/10.1007/s00059-012-3608-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-012-3608-y

Schlüsselwörter

Keywords

Search

Navigation